Search Results
Results found for "Neel Freedman"
- Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic ...
events in non-alcoholic steatohepatitis (NASH), an advanced form of NAFLD, is currently an unmet medical need
- Activation of GPR183 by 7 α,25-Dihydroxycholesterol Induces Behavioral Hypersensitivity through...
Further investigation of the signaling pathways downstream of GPR183 is needed to support the development
- Applications of Fluorescent Probes in Confocal Imaging of GPCRs: From Live to Fixed Cells
, our GPCR fluorescent ligands are designed with a variety of photophysical properties to meet your needs
- Why “Displacement” Misleads You: Allosteric Binding Demystified
Thermodynamics > Intuition: Why the Hall Cube Matters To untangle complex binding behaviors, you need
- Differential binding of Δ9-tetrahydrocannabinol derivatives to type 1 cannabinoid receptors (CB1)
If you are interested in our ligands or technology, feel free to contact me anytime. References 1.
- 🎄 Have Yourself a Merry Little GPCRmas! ❄ Dec 9 - 15, 2024
Your feedback will guide us in tailoring resources , tools , and content to meet your needs better and
- GPCR Allosteric Modulation: Why Allostery is the Engine of Drug Discovery
efficacy, selectivity, and SAR interpretation ✅ Insight into cryptic binding sites and why some drugs need
- Involvement of various chemokine/chemokine receptor axes in trafficking and oriented locomotion ...
Thus, the development of novel and safe medications needs to be considered for the disease management
- 📰 GPCR Weekly News, October 2 to 8, 2023
No registration is needed to submit your logo design. Subscribe now to Dr.
- A robust and Efficient FRET-Based Assay for Cannabinoid Receptor Ligands Discovery.
agents.[1–3] These insights highlight the potential in modulating the ECS to fulfill unmet medical needs potency in the CB1R. [9,10] 1.2 Novel fluorescent strategies for CBR binding affinity assays Thus, the need If you have any questions about CELT-335 or the assays themselves, feel free to contact me!
- How Schild Analysis Protects Your Conclusions in GPCR Research
GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need
- How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs
It began with an unmet need: how to track Gq-coupled GPCR activity without the mess of calcium flux or
- Purpose-Driven Opioid Research: Catherine Demery’s Academic Path
It makes the work feel urgent.”
- 📰 GPCR Weekly News, October 9 to 15, 2023
No registration is needed to submit your logo design. Subscribe to Dr.
- 📰 GPCR Weekly News, June 12 to 18, 2023
Confo Therapeutics and AbCellera partner on GPCR-targeting antibodies GPCR Inhibition With ICB May Be Needed
- Chemical Drug Matter : Rethinking the Molecules We Choose to Develop In Drug Discovery
method-proven insight for discovery teams, pharmacologists refining core skills, and R&D leads who need
- The Truth About GPCR Product Launches: Years in the Making
dose-response with Exendin-4 on GLP-1 receptors—and saw clean, plate-based internalization curves without needing
- The Five Traps of Ignoring Kinetics
you actually use in discovery A growing on-demand library of lessons you can revisit whenever you need
- What's Going On with GPCRs?! Find Out in This Week's Update! ⦿ Nov 4 - 10, 2024
This strategic decision to limit free content is essential as we need to increase revenue to support
- Decoding β-Arrestins: from Structure to function
question of whether β-arrestin1 and 2 serve overlapping or distinct functions remains, raising the need Nonetheless, there is an ongoing need to delve deeper into the intricate mechanisms governing GPCR activation
- Understanding Enzyme Inhibition In GPCR Discovery Programs
GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need
- Targeting GPCRs in the CNS: Advances in Drug Discovery Strategies
their targets are on the membrane of cells, they have easier access to the receptors than those that need
- Why Opposing Processes Matter for Your Next GPCR Drug
section raises a critical design question for teams Are you sure your “antagonist” is enough—or do you need
- 📰 GPCR Weekly News, July 24 to July 30, 2023
Science Crinetics Hosting Key Opinion Leader Webinar To Discuss The Current Treatment Landscape And Unmet Need
- 📰 GPCR Weekly News, September 18 to 24, 2023
You don't need to be registered to participate.
- Discover the Hottest GPCR News of the Week: Oct 7-13, 2024!
Dynamic Learning Environment Tailored to Your Needs Maximize your learning experience by accessing our
- GPCR Collaboration: From Models to Medicine
It also allows Carlsson to stay plugged into the fast-changing needs of biotech while keeping his academic
- Beyond Clearance: The Strategic Power of Irreversible Drug Binding
Dose prediction models need kinetic nuance—not just Cmax and AUC.
- VAMP2: a crucial player in the delivery of MOR to the synapse
been well characterized, the mechanisms that modulate the delivery of GPCRs to the membrane cell still need
- Unlocking the Future of Medicine: Advancements in GPCR Research
Feel free to reach out to us at Hello@DrGPCR.com.




















